For Immediate Release
Chicago, IL – February 17, 2022 – Today, Zacks Equity Research discusses Mettler-Toledo International
MTD
and Bruker
BRKR
.
Industry: Scientific Instruments
Link:
https://www.zacks.com/commentary/1868321/2-stocks-to-buy-on-rising-demand-for-scientific-instruments
The coronavirus pandemic has created unique opportunities for the Zacks
Instruments – Scientific industry
participants —
Mettler-Toledo International
and
Bruker
. These companies are gaining from solid demand for coronavirus testing tools as well as rising instrument orders across the globe. Moreover, increasing health care spending driven by an aging demography and continued innovation in the pharma and life sciences end-markets are key catalysts despite coronavirus-induced macroeconomic uncertainties.
Increasing demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Further, the reopening of university research laboratories as well as applied and industrial labs globally is a driving factor for the near term.
Industry Description
The Zacks Instruments – Scientific industry comprises companies offering scientific instruments, analytical tools, diagnostic solutions, precision instruments & services, and test & sensor solutions. The primary end-markets served by the industry participants are life science research in academia, medical schools and government, pharmaceuticals and biotechnology, microbiology and diagnostics, nanotechnology and materials science research.
A few companies also serve the food and nutritional safety, biochemical, and industrial spaces. Most of the industry participants are under stringent regulatory scrutiny worldwide. They have to adhere to the U.S. Food and Drug Administration (FDA) norms as well as rules set by other global regulatory bodies for serving highly regulated end-markets like life sciences and pharma.
3 Trends Shaping the Future of Instruments-Scientific Industry
Strong End-Market Demand
: The industry is benefiting from strong end-market demand, particularly from the life science, pharmaceutical and academic markets. Increasing demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers.
Additionally, pharma companies are focusing on rapidly growing areas like proteomics and phenomics, biopharma and applied, microbiology and diagnostics, and neuroscience and cell microscopy, which creates significant demand for the instruments provided by industry participants.
Aging Demography Driving Spending
: Socioeconomic factors like an aging demography and increasing environmental regulations are driving demand for scientific measurement solutions. Moreover, robust worldwide healthcare spending is a major growth driver.
Solid Emerging Market Prospects
: Further, the industry is gaining from increasing exposure to developing economies like China and India. Prospects in China are huge as regulators are attempting to raise the country’s biopharma industry to global standards. Moreover, efforts to improve the drug development process and production quality in the country are noteworthy. These factors are resulting in strong demand for instruments.
Zacks Industry Rank Indicates Solid Prospects
The Zacks Instruments – Scientific industry is housed within the broader Zacks
Computer and Technology
sector. It carries a Zacks Industry Rank #55, which places it at the top 22% of more than 250 Zacks industries.
The group’s
Zacks Industry Rank
, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
The industry’s positioning in the top 50% of the Zacks-ranked industries is a result of positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gaining confidence in this group’s earnings growth potential. Since Feb 28, 2021, the industry’s 2022 earnings estimates have moved up 13.2%.
Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.
Industry Beats Sector and S&P 500
The Zacks Instruments – Scientific industry has outperformed the broader Zacks Computer and Technology sector and the S&P 500 composite over the past year.
The industry has risen 16.6% over this period compared with the S&P 500’s increase of 11.9% and the broader sector’s decline of 1.5%.
Industry’s Current Valuation
On the basis of forward 12-month P/E, which is a commonly used multiple for valuing scientific instrument stocks, we see that the industry is currently trading at 29.45X compared with the S&P 500’s 19.7X and the Zacks Computer and Technology sector’s 27.48X.
Over the last five years, the industry has traded as high as 36.33X, as low as 26.32X and at the median of 31.60X.
2 Scientific Instruments Providers to Buy
Mettler-Toledo International
: This Polaris Parkway, Columbus-based company has returned 22.5% in the past year. This Zacks Rank #2 (Buy) company is benefiting from solid momentum across its laboratory and Industrial segments. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
Mettler Toledo’s strengthening presence in the Americas, Europe, Asia and the Rest of the World remains positive. Furthermore, portfolio strength, cost-cutting efforts, robust sales and marketing strategies, benefits from investments in Spinnaker sales, and field resources are contributing well. Also, a strong core industrial business is encouraging. Further, solid demand across pharmaceutical and life science markets is a tailwind.
The Zacks Consensus Estimate for Mettler-Toledo’s current-year earnings has moved up 1.6% to $38.36 per share over the past 30 days.
Bruker
: This Billerica, MA-based company is benefiting from growth in its Nano Group’s microelectronics and semiconductor metrology tools.
This Zacks Rank #2 (Buy) company is riding on strong prospects for CALID Group and BioSpin. Continued growth in mass spectrometry and microbiology businesses, along with strength in the FTIR/Near IR/Raman molecular spectroscopy products lines, has been beneficial for CALID Group.
Bruker’s BioSpin’s solution has been gaining adoption not only among academic and government customers but also from pharmaceutical and biotechnology companies.
Notably, the Zacks Consensus Estimate for Bruker’s 2022 earnings has risen by a penny to $2.29 per share in the past 30 days. The stock has rallied 8.9% in the past year.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Join us on Facebook:
https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
